Could a vaccine tame this rare brain disease?
NCT ID NCT07217665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a vaccine called AADvac1 in 146 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and thinking. The vaccine aims to target a protein linked to the disease and slow its progression. Participants will receive injections over time, and researchers will measure changes in symptoms using a rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AADvac1 (a vaccine targeting tau protein)
What this could lead to
If it works, this could slow the progression of PSP, a rare and devastating brain disease, giving patients more time with better function.
What could go wrong
This is an early Phase 2 trial with only 146 people, so results may not apply to all. The vaccine may not slow the disease or could cause side effects like injection reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSP - PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••